Are HIV patients undertreated? Cardiovascular risk factors in HIV: Results of the HIV-HEART study

European Journal of Preventive Cardiology

Volumn 19, Issue 2, 2012, Pages 267-274

  Reinsch, Nico ^a   Neuhaus, Kathrin ^a   Esser, Stefan ^a   Potthoff, Anja ^b   Hower, Martin ^c   Mostardt, Sarah ^a   Neumann, Anja ^a   Brockmeyer, Norbert H ^b   Gelbrich, Götz ^d   Erbel, Raimund ^a   Neumann, Till ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c KLINIKUM DORTMUND   (Germany)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cardiovascular risk factors; coronary heart disease; Framingham risk score; HIV infection; prevalence; treatment

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84863226094     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711398431     Document Type: Article

References (36)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 ; 338 (13). 853-860 (Pubitemid 28135961)
2. Stein JH, Hadigan CM, Brown TT, Chadwick E, Feinberg J, Friis-Moller N, et al. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation. 2008 ; 118 (2). e54 - e60
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003 ; 362 (9377). 22-29 (Pubitemid 36835816)
4. Koutkia P, Grinspoon S. HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies. Annu Rev Med. 2004 ; 55: 303-317
5. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006 ; 145 (6). 397-406 (Pubitemid 46768570)
6. Ho JE, Hsue PY. Cardiovascular manifestations of HIV infection. Heart. 2009 ; 95 (14). 1193-1202
7. Friis-Moller N, Thiebaut R, Reiss P, Weber R, Monforte AD, De Wit S, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (5). 491-501
8. Gritz ER, Vidrine DJ, Lazev AB, Amick BC, Arduino RC. Smoking behavior in a low-income multiethnic HIV/AIDS population. Nicotine Tob Res. 2004 ; 6 (1). 71-77 (Pubitemid 38372476)
9. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003 ; 37 (2). 292-298 (Pubitemid 36930361)
10. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004 ; 23 (8). 625-630 (Pubitemid 39222637)
11. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006 ; 7 (6). 404-410 (Pubitemid 44123252)
12. Neumann T, Esser S, Potthoff A, Pankuweit S, Neumann A, Breuckmann F, et al. Prevalence and natural history of heart failure in outpatient HIV-infected subjects: rationale and design of the HIV-HEART study. Eur J Med Res. 2007 ; 12 (6). 243-248 (Pubitemid 47248964)
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18 (6). 499-502
14. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19). 2486-2497
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJ, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42 (6). 1206-1252 (Pubitemid 37553153)
16. Gohlke H, Kubler W, Mathes P, Meinertz T, Schuler G, Gysan DB, et al. [Policy paper on primary prevention of cardiovascular diseases. Current draft of 3/25/2003 issued by the Executive Committee of the German Society of Cardiology, Heart and Circulation Research. Edited by the Prevention Project Group on behalf of the Executive Committee]. Z Kardiol. 2003 ; 92 (6). 522-523
17. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007 ; 16 (3). 135-232
18. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007 ; 45 (8). 1074-1081 (Pubitemid 47580361)
19. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007 ; 356 (17). 1723-1735 (Pubitemid 46658704)
20. Bonnet F, Morlat P, Chene G, Mercie P, Neau D, Chossat I, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med. 2002 ; 3 (3). 195-199
21. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Blood Press. 1998 ; 7 (5-6). 262-269 (Pubitemid 29182813)
22. Tonstad S, Andrew Johnston J. Cardiovascular risks associated with smoking: a review for clinicians. Eur J Cardiovasc Prev Rehabil. 2006 ; 13 (4). 507-514 (Pubitemid 44162150)
23. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003 ; 22 (2). 89-99 (Pubitemid 36970166)
24. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y, et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009 ; 10 (6). 378-387
25. da Silva EF, Barbaro G. New options in the treatment of lipid disorders in HIV-infected patients. Open AIDS J. 2009 ; 3: 31-37
26. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 2001 ; 358 (9290). 1322-1327 (Pubitemid 33016496)
27. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dube MP, et al. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008 ; 118 (2). 198-210
28. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 ; 37 (5). 613-627 (Pubitemid 37100800)
29. Lima EM, Gualandro DM, Yu PC, Giuliano Ide C, Marques AC, Calderaro D, et al. Cardiovascular prevention in HIV patients: results from a successful intervention program. Atherosclerosis. 2009 ; 204 (1). 229-232
30. Kulasekaram R, Peters BS, Wierzbicki AS. Dyslipidaemia and cardiovascular risk in HIV infection. Curr Med Res Opin. 2005 ; 21 (11). 1717-1725 (Pubitemid 41667238)
31. Carr A, Hudson J, Chuah J, Mallal S, Law M, Hoy J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS. 2001 ; 15 (14). 1811-1822 (Pubitemid 32939242)
32. Currier JS, Lundgren JD. Guidelines for managing cardiovascular risk: an evolving area. Curr Opin HIV AIDS. 2008 ; 3 (3). 205-206 (Pubitemid 351520999)
33. Gohlke H, Winter M, Karoff M, Held K. CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention. Eur J Cardiovasc Prev Rehabil. 2007 ; 14 (1). 141-148
34. Assmann G, Schulte H, Cullen P. New and classical risk factors-the Munster heart study (PROCAM). Eur J Med Res. 1997 ; 2 (6). 237-242
35. Knobel H, Jerico C, Montero M, Sorli ML, Velat M, Guelar A, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS. 2007 ; 21 (7). 452-457 (Pubitemid 47224837)
36. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Med. 2003 ; 4 (1). 1-10 (Pubitemid 37161530)